SCHEMBL29569065

SCHEMBL29569065

CO/N=C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)c1cscn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 7/20 0.59
▸ HTR2C P28335 1/20 0.59
▸ MAPT P10636 3/20 0.57
▸ PPARG P37231 2/20 0.57
▸ SLC22A6 Q4U2R8 2/20 0.57
▸ SLC22A8 Q8TCC7 2/20 0.57
▸ SLC22A11 Q9NSA0 2/20 0.57
▸ ALB P02768 1/20 0.57
▸ PTGS1 P23219 1/20 0.54
▸ PGR P06401 4/20 0.52
▸ TDP1 Q9NUW8 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ POLB P06746 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ PTGS2 P35354 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10674228 0.90 TDP1 (0.59) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL10674221 0.90 TDP1 (0.59) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL11155800 0.90 TDP1 (0.59) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL11010391 0.87 NR1I2 (0.76) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL10606264 0.86 TDP1 (0.72) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL10606259 0.86 TDP1 (0.72) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL11009334 0.86 NR1I2 (0.57) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL11009331 0.86 NR1I2 (0.57) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL10671707 0.85 TDP1 (0.49) NR1I2HTR2CMAPTPPARGSLC22A6
SCHEMBL10671700 0.85 TDP1 (0.49) NR1I2HTR2CMAPTPPARGSLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM UNIV CALIFORNIA (US) 2025-12-11 — — US disclosed
US-20250313905-A1 METHODS AND COMPOSITIONS FOR IMPROVED PSYCHOLOGICAL AND RESILIENCE MEASURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-10-09 — — US disclosed
US-12364717-B2 Compositions and methods for inhibiting seizures THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-07-22 — — US disclosed
US-12292445-B2 Methods of selecting subjects for treatment with metabolomic modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-05-06 — — US disclosed
EP-4525896-A1 METHODS AND COMPOSITIONS FOR IMPROVED PSYCHOLOGICAL AND RESILIENCE MEASURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-03-26 — — EP disclosed
WO-2025038777-A2 PROBIOTICS AND METHODS TO REDUCE APPETITE BLOOM SCIENCE, INC. (US) 2025-02-20 — — WO disclosed
EP-4509174-A2 COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH The Regents of the University of California (US) 2025-02-19 — — EP disclosed
US-20250025516-A1 COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-01-23 — — US disclosed
CN-119033822-A Compositions and methods for inhibiting seizures 加利福尼亚大学董事会 2024-11-29 — — CN disclosed
WO-2024233640-A1 COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-14 — — WO disclosed
US-20230310515-A1 COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-05 — — US disclosed
WO-2023114180-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-22 — — WO disclosed
WO-2023102170-A1 COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-08 — — WO disclosed
WO-2022243703-A1 METHOD OF PROGNOSIS PLAQUETEC LTD (GB) 2022-11-24 — — WO disclosed
US-20220257646-A1 COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-08-18 — — US disclosed
US-20220218762-A1 COMPOSITIONS AND METHODS FOR MODULATING COGNITIVE BEHAVIOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-07-14 — — US disclosed
US-20220184144-A1 COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-06-16 — — US disclosed
EP-4003381-A1 COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES The Regents of the University of California (US) 2022-06-01 — — EP disclosed
EP-3999076-A1 COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS The Regents of the University of California (US) 2022-05-25 — — EP disclosed
EP-3976026-A2 COMPOSITIONS AND METHODS FOR MODULATING COGNITIVE BEHAVIOR The Regents of the University of California (US) 2022-04-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM CYP27A1, LIPC, CYP46A1 NR1I2 667/4885HTR2C 4394/4885MAPT 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback